Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Protagonist Therapeutics (PTGX) over the last 5 years, with Dec 2024 value amounting to $4.23.

  • Protagonist Therapeutics' EPS (Weighted Average and Diluted) fell 14.81% to -$0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.65, marking a year-over-year decrease of 76.28%. This contributed to the annual value of $4.23 for FY2024, which is 404.32% up from last year.
  • According to the latest figures from FY2024, Protagonist Therapeutics' EPS (Weighted Average and Diluted) is $4.23, which was up 404.32% from -$1.39 recorded in FY2023.
  • Protagonist Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $4.23 for FY2024, and its period low was -$2.71 during FY2021.
  • For the 3-year period, Protagonist Therapeutics' EPS (Weighted Average and Diluted) averaged around $0.08, with its median value being -$1.39 (2023).
  • Per our database at Business Quant, Protagonist Therapeutics' EPS (Weighted Average and Diluted) slumped by 41.15% in 2021 and then spiked by 404.32% in 2024.
  • Protagonist Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$1.92 in 2020, then slumped by 41.15% to -$2.71 in 2021, then climbed by 4.06% to -$2.60 in 2022, then soared by 46.54% to -$1.39 in 2023, then spiked by 404.32% to $4.23 in 2024.